Form 4: SCYNEXIS Director Steven Gilman Granted 23,000 Shares and Options as Equity Compensation

SCYNEXIS Inc. Director Steven C. Gilman was granted 23,000 shares of common stock and 23,000 stock options, effective June 26, 2025, as part of his compensation package.

Summary

• Director Steven C. Gilman of SCYNEXIS Inc. was granted 23,000 shares of common stock and 23,000 stock options.
• The transaction date for both grants is June 26, 2025.
• The common stock grant is in the form of restricted stock units, which will vest 100% on the first anniversary of the grant date, contingent on continuous service by the non-employee director.
• The stock options have an exercise price of $0.74 and are set to expire on June 25, 2035.
• The options also vest 100% on the first anniversary of the grant date, contingent on continuous service by the non-employee director.
• Following these transactions, Steven C. Gilman beneficially owns 70,000 shares of common stock directly and 23,000 stock options directly.

Sentiment

Score: 7

Explanation: The grant of equity to a director is generally a positive signal, indicating alignment of interests and confidence in the company's future. It's a standard compensation practice, not an extraordinary event, hence not a perfect 10.

Positives

• The grant of restricted stock units and stock options to a director aligns their interests with shareholders, incentivizing long-term performance and value creation.
• The acquisition of additional equity by a director can signal confidence in the company's future prospects and strategic direction.

Risks

• The vesting of both the restricted stock units and stock options is contingent on the non-employee director providing continuous services for one year from the grant date.

Future Outlook

The vesting schedule for the granted equity indicates a future milestone for the director's compensation, contingent on continued service to the company.

Industry Context

This transaction represents a standard form of equity compensation for non-employee directors, commonly utilized across publicly traded companies, particularly in the biotechnology or pharmaceutical industry, to align director incentives with long-term shareholder value creation.

Comparison to Industry Standards

• Equity grants, including restricted stock units and stock options, are a common component of non-employee director compensation across publicly traded companies, especially in growth-oriented sectors like biotech.
• The vesting period of one year is typical for such grants, aligning with practices observed at comparable smaller-cap biotech firms.
• The exercise price of $0.74 for the options is likely the fair market value of the stock on the grant date, which is a standard practice for incentive stock options.

Related Party Transactions

• The equity grants to Steven C. Gilman, a director of SCYNEXIS Inc., constitute related party transactions as they involve compensation from the company to an insider.

Stakeholder Impact

• Shareholders: The grants align the director's financial interests with those of shareholders, potentially leading to better long-term decision-making and value creation.
• Employees: No direct impact on employees is indicated.
• Customers: No direct impact on customers is indicated.
• Suppliers: No direct impact on suppliers is indicated.
• Creditors: No direct impact on creditors is indicated.

Next Steps

• The restricted stock units and stock options are scheduled to vest on the first anniversary of the June 26, 2025 grant date, provided the director continues to provide services.

Key Dates

Recommendation

Keywords

SCYNEXIS, SCYX, Steven C. Gilman, Form 4, SEC filing, insider transaction, stock grant, restricted stock units, stock options, director compensation, equity compensation